Enhancement of antineoplastic action of 5-aza-2′-deoxycytidine by zebularine on L1210 leukemia

Anti-Cancer Drugs

Volumn 16, Issue 3, 2005, Pages 301-308

  Lemaire, Maryse ^a   Momparler, Louise F ^a   Bernstein, Mark L ^b   Marquez, Victor E ^c   Momparler, Richard L ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

5 aza 2 deoxycytidine; Chemotherapy; Cytidine deaminase; DNA methylation; Leukemia; p57KIP2 expression; Zebularine

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CYTIDINE DEAMINASE; PROTEIN P57; ZEBULARINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; GENE ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LEUKEMIA L 1210; LYMPHATIC LEUKEMIA; MALE; MOUSE; MYELOID LEUKEMIA; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; TUMOR SUPPRESSOR GENE; WEIGHT REDUCTION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CELL LINE, TUMOR; CYTIDINE; CYTIDINE DEAMINASE; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; LEUKEMIA L1210; MALE; MICE; PYRIMIDINE NUCLEOSIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR STEM CELL ASSAY;

EID: 14144255400     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200503000-00009     Document Type: Article

References (34)

1. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999; 21:163-167.
2. Momparler RL. Cancer epigenetics. Oncogene 2003; 22:6479-6483.
3. Momparler RL, Bovenzi V. DNA methylation and cancer. J Cell Physiol 2000; 183:145-154.
4. Momparler RL, Derse D. Kinetics of phosphorylation of 5-aza-2′-deoxycytidine by deoxycytidine kinase. Biochem Pharmacol 1979; 28:1443-1444.
5. Momparler RL. Molecular, cellular and animal pharmacology of 5-aza-2′-deoxycytidine. Pharmacol Ther 1985; 30:287-399.
6. Bouchard J, Momparler RL. Incorporation of 5-aza-2′-deoxycytidine 5′-triphosphate into DNA interactions with mammalian DNA polymerase and DNA methylase. Mol Pharmacol 1983; 24:109-114.
7. Jüttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2′- deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 1994; 91:11797-11801.
8. Chabot GG, Bouchard J, Momparler RL. Kinetics of deamination of 5-aza-2′-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside. Biochem Pharmacol 1983; 32:1327-1328.
9. Eliopoulos N, Coumoyer D, Momparler RL. Drug resistance to 5-aza-2′-deoxycytidine, 2′-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells. Cancer Chemother Pharmacol 1998; 42:373-378.
10. Momparler RL, Momparler LF, Samson J. Comparison of the antileukemic activity of 5-aza-2′-deoxycytidine, 1-β-D-arabinofuranosyl-cytosine and 5-azacytidine against L1210 leukemia. Leuk Res 1984; 8:1043-1049.
11. Wilson VL, Jones PA, Momparler RL. Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2′-deoxycytidine as a possible mechanism for chemotherapeutic action. Cancer Res 1983; 43:3493-3497.
12. Rivard GE, Momparler RL, Demers J, Benoit P, Raymond R, Lin K, et al. Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leuk Res 1981; 5:453-462.
13. Onetto N, Momparler RL, Momparler LF, Gyger M. In vitro biochemical tests to evaluate the response to therapy of acute leukemia with cytosine arabinoside or 5-AZA-2′-deoxycytidine. Semin Oncol 1987; 14(suppl 1):231-237.
14. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004; 103:1635-1640.
15. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G, Wijermans P, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood 2002; 100:2957-2964.
16. Ho DH. Distribution of kinase and deaminase of 1-beta-D- arabinofuranosylcytosine in tissues of man and mouse. Cancer Res 1973; 33:816-820.
17. Momparler RL, Côté S, Eliopoulos N. Pharmacological approach for optimization of the dose-schedule of 5-aza-2′-deoxycytidine (Decitabine) for the therapy of leukemia. Leukemia 1997; 11:175-180.
18. Carlow D, Wolfenden R. Substrate connectivity effects in the transition state for cytidine deaminase. Biochemistry 1998; 37:11873-11878.
19. Frick L, Yang C, Marquez VE, Wolfenden R. Binding of pyrimidin-2-one ribonucleoside by cytidine deaminase as the transition-state analogue 3,4-dihydrouridine and the contribution of the 4-hydroxyl group to its binding affinity. Biochemistry 1989; 28:9423-9430.
20. Laliberté J, Marquez VE, Momparler RL. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2′-deoxycytidine by human cytidine deaminase. Cancer Chemother Pharmacol 1992; 30:7-11.
21. Zhou L, Cheng X, Connolly BA, Dickman MJ, Hurd PJ, Hornby DP. Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol 2002; 23:591-599.
22. Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, Marquez VE, et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 2003; 95:399-409.
23. Cheng JC, Weisenberger DJ, Gonzales FA, Gangning L, Xu GL, Hu YG, et al. Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 2004; 24:1270-1278.
24. Kelley JA, Driscoll JS, McCormack JJ, Roth JS, Marquez VE. Furanose-pyranose isomerization of reduced pyrimidine and cyclic urea ribosides. J Med Chem 1986; 29:2351-2358.
25. Driscoll JS, Marquez VE, Plowman J, Liu PS, Kelley JA, Barchi Jr JJ. Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues. J Med Chem 1991; 34:3280-3284.
26. KIP2 gene in the promoter region in lymphoid malignancies of B-cell phenotype. Blood 2002; 100:2572-2577.
27. Shen L, Toyota M, Kondo Y, Obata T, Daniel S, Pierce S, et al. Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood 2003; 101:4131-4136.
28. Lemaire M, Momparler LF, Marquez VE, Bernstein ML, Momparler RL. Enhancement of antineoplastic action of 5-aza-2′-deoxycytidine on L1210 leukemics cells by zebularine, an inhibitor of cytidine deaminase and DNA methyltransferase. Proc Am Ass Cancer Res 2004; 45:366.
29. Momparler RL, Gonzales FA. Effect of intravenous infusion of 5-aza-2′-deoxycytidine on survival time of mice with L1210 leukemia. Cancer Res 1978; 38:2673-2678.
30. Boyd VL, Zon G. Bisulfite conversion of genomic DNA for methylation analysis: protocol simplification with higher recovery applicable to limited samples and increase throughput. Anal Biochem 2004; 326:278-280.
31. Herman JG, Jen J, Merlo A, Baylin SB. Hypermethylation-associated inactivation indicates a tumor suppressor role for P15 (INK4B). Cancer Res 1996; 56:722-727.
32. Valeriote F, Lin H. Synergistic interaction of anticancer agents: a cellular perspective. Cancer Chemother Rep 1975; 59:895-900.
33. Momparler RL. In vitro systems for evaluation of combination chemotherapy. Pharmacol Ther 1980; 8:21-35.
34. Momparler RL, Laliberté J. Induction of cytidine deaminase in HL-60 myeloid leukemic cells by 5-aza-2′-deoxycytidine. Leuk Res 1990; 14:751-754.